Developing an ideal paediatric formulation is crucial to ensuring children receive safe, effective, and accessible cancer therapies. By establishing clear product expectations, Target Product Profiles (TPPs) play a vital role in guiding the development of age-appropriate medicines that enhance treatment outcomes and minimize risks for children battling cancer.

On 18 January 2024, the World Health Organization (WHO) developed its first-ever list of priority paediatric cancer formulations, aiming to focus research and development on the specific needs of children. Following this, leveraging the expertise of partners in the Global Accelerator for Paediatric Formulations Network (GAP-f) a Target Product Profile (TPP) development group was convened to define optimal and minimum attributes for the 6 priority formulations to be developed.

WHO is now seeking feedback on the draft TPPs developed for cyclophosphamide, etoposide, mercaptopurine, methotrexate, procarbazine, and temozolomide. 

Join the public consultation to support WHO in providing clear guidance for manufacturers and product developers to guarantee that these essential medicines meet the needs of children worldwide.